open access publication

Article, 2024

Radiation Therapy Plays an Important Role in the Treatment of Atypical Teratoid/Rhabdoid Tumors: Analysis of the EU-RHAB Cohorts and Their Precursors

International Journal of Radiation Oncology • Biology • Physics, ISSN 1879-355X, 0360-3016, Volume 119, 4, Pages 1147-1157, 10.1016/j.ijrobp.2024.01.200

Contributors

Frisch, Sabine [1] Libuschewski, Hanna [1] Peters, Sarah [1] Gerss, Joachim Werner Otto 0000-0003-3489-683X [2] Von Hoff, Katja 0000-0002-5669-8546 [3] [4] Kortmann, Rolf-Dieter 0000-0002-8952-1819 [5] Nemes, Karolina [6] Rutkowski, Stefan 0000-0002-5446-9571 [7] Hasselblatt, Martin 0000-0003-2707-8484 [8] Pietsch, Torsten 0000-0003-0763-6506 [9] Frühwald, Michael Christoph 0000-0002-8237-1854 [6] Timmermann, Beate 0000-0003-2274-2008 (Corresponding author) [1]

Affiliations

  1. [1] Essen University Hospital
  2. [NORA names: Germany; Europe, EU; OECD];
  3. [2] University of Münster
  4. [NORA names: Germany; Europe, EU; OECD];
  5. [3] Aarhus University
  6. [NORA names: AU Aarhus University; University; Denmark; Europe, EU; Nordic; OECD];
  7. [4] Aarhus University Hospital
  8. [NORA names: Central Denmark Region; Hospital; Denmark; Europe, EU; Nordic; OECD];
  9. [5] Leipzig University
  10. [NORA names: Germany; Europe, EU; OECD];

Abstract

PURPOSE: Atypical teratoid/rhabdoid tumor (AT/RT) is a rare malignancy of the central nervous system in young children with a dismal prognosis. Prognostic markers have been extensively investigated but have not been validated. The role of radiation therapy (RT) remains controversial. We evaluated the impact of RT as part of multimodality treatment by analyzing data of a European AT/RT cohort. METHODS AND MATERIALS: We retrospectively analyzed data of the European Registry for Rhabdoid Tumors and its precursors. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Potential impact of prognostic factors was analyzed using univariable and multivariable Cox regression analyses with RT as a time-dependent factor. RESULTS: Data of 186 children (118 male, 68 female) treated from 1990 to 2016 were evaluable. The median age at diagnosis was 1.57 years (range, 0.01-26.70 years); 47% (87/186) of the patients were under the age of 18 months. Sixty-nine percent (128/186) received RT (focal RT, n = 93; craniospinal treatment with local boost, n = 34; spinal irradiation, n = 1). The median follow-up duration of the entire cohort was 1.73 years (range, 0.06-20.11 years). The estimated PFS and OS rates were 48% (95% CI, 41%-55%) and 72% (95% CI, 65%-78%) at 1 year and 33% (95% CI, 26%-40%) and 49% (95% CI, 41%-56%) at 2 years, respectively. On multivariable analysis, RT was an independent significant prognostic factor for PFS (hazard ratio, 0.45; 95% CI, 0.27-0.75; P = .002) and OS (hazard ratio, 0.54; 95% CI, 0.32-0.93; P = .025). CONCLUSIONS: This analysis confirms the relevance of local therapies. RT was an independent prognostic factor for outcomes in children experiencing AT/RT. However, long-term sequelae have to be carefully evaluated and considered given the young age at time of RT.

Keywords

AT/RT, Cox regression analysis, European, European Registry, OS rates, Rhabdoid, age, analysis, atypical teratoid/rhabdoid tumor, central nervous system, children, cohort, data, diagnosis, dismal prognosis, duration, endpoint, factors, follow-up duration, impact, impact of RT, impact of prognostic factors, local therapy, long-term sequelae, malignancy, markers, median age, median follow-up duration, months, multimodal treatment, multimodality, multivariate Cox regression analysis, multivariate analysis, nervous system, outcomes, overall survival, patients, potential impact, precursor, primary endpoint, prognosis, prognostic factors, prognostic marker, progression-free survival, radiation, radiation therapy, rare malignancy, rate, registry, regression analysis, relevance, rhabdoid tumor, sequelae, survival, system, teratoid/rhabdoid tumor, therapy, treatment, tumor, years, young children, younger age

Funders

  • Deutsche Kinderkrebsstiftung
  • European Commission

Data Provider: Digital Science